Table 1.
| Component | Description |
|---|---|
| Breast cancer molecular subtype | portrayal of four distinct molecular subtypes based on estrogen receptor (ER) and human epidermal growth factor-2 receptor (HER2) status, each with its own underlying natural history (survival, sojourn times, screen detectability, and impact of therapeutic advances on survival) |
| Incidence | incidence of breast cancer to reflect the current trends in underlying risk and by molecular subtype |
| Non-breast cancer mortality | non-breast cancer mortality inputs to reflect changes in medical care and competing causes of death |
| Screening dissemination | the use and dissemination of digital mammography |
| Accuracy of mammography | sensitivity and specificity of film and digital mammography with recent data reflecting the improvements in the accuracy of mammography over time |
| Treatment dissemination | dissemination of the most current therapies including anthracyclines, taxanes, and herceptin |
| Treatment effectiveness | treatment effectiveness using data from more recent trials |
| Risk factors | risk factors such as breast density, postmenopausal hormone use and body mass index are added to some models |
| Ductal carcinoma in situ (DCIS) | DCIS representations in the models have been improved |
| Comorbidities | Some models have been updated to account for comorbidities |
CISNET, Cancer Intervention and Surveillance Modeling Network.
Feuer EJ. Modeling the impact of adjuvant therapy and screening mammography on US breast cancer mortality between 1975 and 2000: introduction to the problem. Journal of the National Cancer Institute. Monographs. 2006(36):2–6.
Mandelblatt JS, Near AM, Miglioretti DL, et al. Common Model Inputs in Collaborative Breast Cancer Modeling Medical Decision Making. 2017;In Press.
Lee SJ, Li X, Huang H. Models for Breast Cancer Screening Strategies Updated for Ductal Carcinoma In Situ and Subgroups Medical Decision Making. 2017;In Press.
van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning H. Estimating the effects of risk-based screening and adjuvant treatment using the MISCAN-Fadia continuous tumor growth model for breast cancer Medical Decision Making. 2017;In Press.
Schechter CB, Near AM, Jayasekera J, Chang Y, Mandelblatt JS. Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model Medical Decision Making. 2017;In Press.
Huang, Xuelin, Li Y, Song J, Berry D. A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality Medical Decision Making. 2017;In Press.
Alagoz, Oguzhan, Ergun MA, Cevik M, et al. The University Of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update Medical Decision Making. 2017;In Press.
Munoz D, Xu C, Plevritis SK. A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence and Mortality Trends from 1975 to 2010. Medical Decision Making. 2017;In Press.